Technology
FDA pilot program allows select generative AI medical devices to launch prior to authorization
The agency's TEMPO pilot permits four digital health tools to enter the market provisionally in support of a Medicare chronic care model.
The short version
- The FDA is provisionally allowing select digital health companies to release generative AI medical devices without prior marketing authorization.
- Four devices, including AI tools developed by Cadence and Limbic, have been admitted to the agency's TEMPO pilot program.
- The initiative is designed to expand technology options for Medicare's ACCESS model for chronic condition management while testing real-world AI oversight frameworks.
- It remains to be seen how the FDA will evaluate the performance and safety of these devices under the pilot before granting formal authorization.
Key facts
- The FDA's TEMPO pilot program is provisionally permitting certain developers to deploy generative AI medical devices to patients before receiving formal marketing authorization.[STAT]
- Four medical devices have been admitted into the TEMPO pilot, including generative AI products from Limbic and Cadence.[STAT]
- The pilot is intended to provide additional digital health tools for the Medicare ACCESS model, which evaluates payment approaches for chronic condition management technologies.[STAT]
What remains uncertain
- The specific regulatory conditions, monitoring metrics, and eventual requirements for permanent marketing authorization under the TEMPO pilot have not been fully detailed in available reporting.[STAT]